Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Sessi
Syndax Pharmaceuticals (SNDX) shares fell 17.2% to $13.70 in pre-market trading after its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint. Other stocks moving lower include BioNTech (BNTX), down 6.1% to $90.01, and Seagate (STX), down 5.7% to $710.10, among others.
How this was made
The 30-second read
Why it matters
A primary-endpoint miss is typically a high-signal negative catalyst for biotech valuation, increasing uncertainty around future development and potential partnering or regulatory paths.
Market read
Traders can use the pre-market clinical-trial failure to reassess near-term risk, liquidity, and potential follow-through selling.
What to watch
Investors may overreact without details on effect size, variability, or whether the endpoint miss was driven by enrollment mix or protocol deviations.
Background
The piece is a pre-market movers roundup, with the main company-specific item being Syndax’s Phase 2 clinical-trial outcome.
Ticker impact
Syndax shares fell in pre-market after its MAXPIRe Phase 2 axatilimab trial in idiopathic pulmonary fibrosis missed the primary endpoint.
Likely continued pressure as the market digests the missed primary endpoint and reduces probability-weighted value.
The article cites a specific Phase 2 primary-endpoint miss, which is a direct, company-specific catalyst for biotech risk repricing.
Market effects
Adds to negative sentiment around late-stage IPF and oncology-adjacent biotech trial outcomes, potentially pressuring clinical-stage peers.
Primarily US biotech risk, with limited spillover beyond pre-market movers.
Mostly contained to global biotech sentiment; no cross-market policy or macro catalyst cited.
Counterpoint
A single missed primary endpoint may still leave secondary endpoints, subgroup signals, or alternative trial designs that could limit long-term damage.
Key entities
- companySyndax Pharmaceuticals, Inc
Announced its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet the primary endpoint.
